Brief: Briacell Announces Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer At 2022 San Antonio Breast Cancer Symposium
08/12/2022 15:51
Dec 8 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL ANNOUNCES POSITIVE CLINICAL AND QUALITY OF LIFE
DATA IN
ADVANCED METASTATIC BREAST CANCER AT 2022 SAN ANTONIO BREAST
CANCER SYMPOSIUM®
Source text for Eikon: ID:nGNX1ZMSgB
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study